Symbiotec Pharmalab
Symbiotec Pharmalab (SYMBIOTEC) share price was ₹1,277.80 at the 27 Oct 2026 close; sector Healthcare. In the Jun 2026 quarter, revenue rose 7.4% year on year to ₹218 Cr and net profit was ₹14 Cr, against ₹30 Cr a year earlier (compared with Jun 2025). Promoters held 33.28% of Symbiotec Pharmalab in Sep 2026.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,757.50 | 34.86 | 4,21,683 Cr | 5.05 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,558.50 | 86.75 | 2,53,748 Cr | 15.14 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,557.00 | 71.54 | 1,73,334 Cr | 9.43 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,181.90 | 107.80 | 1,17,891 Cr | 22.24 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,175.50 | 26.16 | 1,17,257 Cr | 4.33 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,335.40 | 34.59 | 1,11,463 Cr | 2.87 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.60 | 32.72 | 1,10,321 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| ₹1,274.70 | 102.80 | 8,191 Cr | 6.30 | 0.00% | 9.56% | 14.26% | 670 Cr | 72 Cr | |
| Symbiotec Pharmalab (this company) | ₹1,274.70 | — | — | — | — | — | — | — | — |
| Median 9 companies | ₹1,365.60 | 53.20 | 1,17,574 Cr | 5.68 | 0.47% | 12.98% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Company has reduced debt.
Weaknesses
3- Promoter holding is low: 33.3%
- Company has a low return on equity of 12.9% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
Oscillators
Bullish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 203 | 245 | 218 |
| Expenses | 145 | 183 | 173 |
| Operating Profit | 58 | 62 | 45 |
| OPM % | 29% | 25% | 21% |
| Other Income | 3 | 0 | 0 |
| Interest | 5 | 7 | 6 |
| Depreciation | 11 | 20 | 22 |
| PBT | 45 | 35 | 18 |
| Tax % | 33% | 22% | 20% |
| Net Profit | 30 | 28 | 14 |
| EPS (₹) | 46.99 | 4.39 | 2.24 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 633 | 682 | 567 | 716 | 752 | 869 |
| Expenses | 438 | 550 | 497 | 544 | 549 | 630 |
| Operating Profit | 195 | 131 | 70 | 172 | 203 | 239 |
| OPM % | 31% | 19% | 12% | 24% | 27% | 27% |
| Other Income | 7 | 3 | 6 | 7 | 4 | -6 |
| Interest | 7 | 3 | 8 | 8 | 17 | 26 |
| Depreciation | 22 | 26 | 29 | 39 | 43 | 53 |
| PBT | 173 | 105 | 39 | 132 | 147 | 153 |
| Tax % | 28% | 27% | 38% | 23% | 34% | 28% |
| Net Profit | 123 | 78 | 23 | 100 | 97 | 110 |
| EPS (₹) | 113 | 70.89 | 21.48 | 91.49 | 152 | 17.51 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 13 |
| Reserves | 510 | 588 | 611 | 704 | 804 | 1,137 |
| Borrowings | 47 | 65 | 218 | 247 | 544 | 391 |
| Other Liabilities | 200 | 152 | 151 | 326 | 220 | 240 |
| Total Liabilities | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
| Fixed Assets | 261 | 280 | 299 | 448 | 438 | 1,120 |
| CWIP | 28 | 40 | 182 | 208 | 568 | 64 |
| Investments | 5 | 5 | 5 | 4 | 1 | 4 |
| Other Assets | 474 | 490 | 504 | 628 | 572 | 592 |
| Total Assets | 768 | 815 | 990 | 1,289 | 1,580 | 1,781 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 174 | 18 | 69 | 188 | 47 | 175 |
| Investing | -96 | -32 | -220 | -206 | -307 | -227 |
| Financing | -79 | 15 | 146 | 22 | 278 | 36 |
| Net Cash Flow | -1 | 1 | -5 | 3 | 19 | -16 |
| Free Cash Flow | 87 | -55 | -155 | -22 | -261 | -50 |
| CFO/OP | 112 | 36 | 124 | 129 | 40 | 99 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 77 | 72 | 64 | 85 | 83 |
| Inventory Days | 308 | 252 | 305 | 382 | 321 | 274 |
| Days Payable | 155 | 91 | 110 | 259 | 109 | 160 |
| Cash Conversion Cycle | 221 | 238 | 267 | 187 | 298 | 197 |
| Working Capital Days | 86 | 121 | 107 | 76 | -3 | -22 |
| ROCE % | — | 18% | 6% | 16% | 14% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Symbiotec Pharmalab insights
51 extracted metrics + investor summaries across FY21–FY27.
Documents
Frequently Asked Questions about Symbiotec Pharmalab
What does Symbiotec Pharmalab Ltd do?
Where is Symbiotec Pharmalab Ltd (SYMBIOTEC) listed?
Which sector does Symbiotec Pharmalab Ltd belong to?
What is the 52-week high and low of Symbiotec Pharmalab Ltd?
Company Information
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/1286120.md for Symbiotec Pharmalab Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.